RecruitingNot ApplicableNCT07355634
Terraflora Daily Care and Gastrointestinal Health
A Randomized, Placebo-Controlled Trial Evaluating the Impact of a Synbiotic Dietary Supplement on Markers of Gastrointestinal Health
Sponsor
OvationLab
Enrollment
40 participants
Start Date
Jan 12, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
A 12-week, randomized, double-blind, placebo-controlled clinical trial will be conducted evaluating the effectiveness of Enviromedica - Terraflora Daily Care on markers of gastrointestinal function and symptoms.
Eligibility
Min Age: 25 Years
Inclusion Criteria3
- Adult males or females age ≥ 25 years
- Ability to read and speak English
- Dysbiosis (≥3 on GA-Map Dysbiosis Score) on a stool test (GI360 Profile, Doctor's Data, St. Charles, Illinois)
Exclusion Criteria9
- Daily use within the past month of any probiotic or prebiotic supplement
- Current diagnosis of inflammatory bowel disease, including Crohn's or ulcerative colitis
- Current daily usage of non-steroidal anti-inflammatory drugs (NSAID), proton pump inhibitors (PPI), or antibiotic medications
- Current daily tobacco smoker
- Known allergies to any substance in the study products
- Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks
- Current diagnosis of any other chronic health condition (e.g., cancer, chronic kidney disease) deemed clinically contraindicated for the study protocol
- Current participation in another clinical trial
- Participants unable to provide consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIETARY_SUPPLEMENTSynbiotic Dietary Supplement
12 weeks of supplementation with Enviromedica - Terraflora Daily Care
DIETARY_SUPPLEMENTPlacebo
Placebo capsule
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07355634